Page 11 - Read Online
P. 11

Page 2 of 3                                         Fang. J Cancer Metastasis Treat 2020;6:1  I  http://dx.doi.org/10.20517/2394-4722.2019.42
                             [6]
               and Kolmakova  reviewed current advances in searching for circulating biomarkers for pediatric brain
               tumors, including cell-free DNA, non-coding RNA, tumor metabolites, and proteins in body fluids, such
                                                                                                [7]
               as cerebrospinal fluid, blood, and urine. On the other hand, the review article by Farlow et al.  discussed
               applications of biomarkers in design of clinical trials. These reviews and discussions on advances and
               challenges in biomarker discoveries stimulate new thinking on addressing the challenges encountered in
               the field of cancer biomarker discoveries and precision therapies.

               The authors of four original articles reported results of their research projects on the discovery of new
                                                    [8]
               cancer biomarkers. Vander Borght et al.  described the generation and evaluation of monoclonal
               antibodies specific for exon 18 neural cell adhesion molecule for detecting small cell lung cancer cells.
                             [9]
               Ossoliński et al.  reported their study on mass spectrometry-based metabolomics profiling of prostate
               cancer. They found over two hundred differentiating metabolites in urine, serum, and interstitial fluid of
                                                                     [10]
               prostate cancer patients. The study presented by Zaichick et al.  showed that contents of several chemical
               elements were drastically different between thyroid malignant tumors and normal thyroid tissues. Finally,
                       [11]
               Liu et al.  reported the results of using visible resonance Raman spectroscopy for rapid skin cancer
               diagnosis.

               I hope you enjoy reading the articles in this Special Issue on biomarker discoveries. I also want to thank
               Dina Li for her assistance in organizing this Special Issue.


               DECLARATIONS
               Authors’ contributions
               The author contributed solely to the article.


               Availability of data and materials
               Not applicable.


               Financial support and sponsorship
               None.


               Conflicts of interest
               Not applicable.

               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2020.

               REFERENCES
               1.   Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, et al. Cancer screening in the United States, 2019: A review of
                   current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2019;69:184-210.
               2.   Sturgeon CM, Hoffman BR, Chan DW, Ch’ng SL, Hammond E, et al. National Academy of Clinical Biochemistry Laboratory Medicine
                   Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008;54:e1-10.
               3.   Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood
                   test. Science 2018;359:926-30.
               4.   Lai RC, Tan KH, Lim SK. Membrane lipid binding molecules for the isolation of bona fide extracellular vesicle types and associated
   6   7   8   9   10   11   12   13   14   15   16